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ABSTRACT
Objectives: Real-life data on response to Botulinum
toxin A (BoNT-A) in cervical dystonia (CD) are
sparse. An expert group of neurologists was
convened with the overall aim of developing
a deﬁnition of treatment response, which could
be applied in a non-interventional study of
BoNT-A-treated subjects with CD.
Design: International, multicentre, prospective,
observational study of a single injection cycle of
BoNT-A as part of normal clinical practice.
Setting: 38 centres across Australia, Belgium, Czech
Republic, France, Germany, The Netherlands, Portugal,
Russia and the UK.
Participants: 404 adult subjects with idiopathic CD.
Most subjects were women, aged 41e60 years and
had previously received BoNT-A.
Outcome measures: Patients were classiﬁed as
responders if they met all the following four criteria:
magnitude of effect ($25% improvement Toronto
Western Spasmodic Torticollis Rating Scale), duration
of effect ($12-week interval between the BoNT-A
injection day and subject-reported waning of treatment
effect), tolerability (absence of severe related adverse
event) and subject’s positive Clinical Global
Improvement (CGI).
Results: High rates of response were observed for
magnitude of effect (73.6%), tolerability (97.5%) and
subject’s clinical global improvement (69.8%). The
subjective duration of effect criterion was achieved by
49.3% of subjects; 28.6% of subjects achieved the
responder deﬁnition. Factors most strongly associated
with response were age (<40 years; OR 3.9, p<0.05)
and absence of baseline head tremor (OR 1.5; not
signiﬁcant).
Conclusions: Three of four criteria were met by most
patients. The proposed multidimensional deﬁnition of
response appears to be practical for routine practice.
Unrealistically high patient expectation and subjectivity
may inﬂuence the perception of a quick waning of
effect, but highlights that this aspect may be a hurdle
to response in some patients.
Clinical registration number: (NCT00833196;
ClinicalTrials.gov).
INTRODUCTION
Cervical dystonia (CD) is the most common
of the focal dystonias,
1 with a prevalence of
89 per million in parts of the US (Rochester,
Minnesota).
2 Any muscle in the neck may
be abnormally contracted in CD. Sets of
contracted muscles can be found in isolation
but are most commonly found in combina-
tion.
3 The majority of cases (w66%) present
with rotational torticollis and laterocollis.
4
Classiﬁcation of CD is based on the primary
(idiopathic) or secondary aetiology
(eg, dystonia because of a brain tumour).
5
Botulinum toxin A (BoNT-A) is a neurotoxin
that is isolated and puriﬁed from Clostridium
botulinum type A bacteria and has gained
increasing acceptance as a ﬁrst-line treatment
To cite: Misra VP, Ehler E,
Zakine B, et al. Factors
inﬂuencing response to
Botulinum toxin type A in
patients with idiopathic
cervical dystonia: results
from an international
observational study. BMJ
Open 2012;2:e000881.
doi:10.1136/
bmjopen-2012-000881
< Prepublication history for
this paper is available online.
To view these ﬁles please
visit the journal online (http://
dx.doi.org/10.1136/
bmjopen-2012-000881).
For author footnote see end
of the article.
Received 16 January 2012
Accepted 14 May 2012
This ﬁnal article is available
for use under the terms of
the Creative Commons
Attribution Non-Commercial
2.0 Licence; see
http://bmjopen.bmj.com
For numbered afﬁliations see
end of article.
Correspondence to
Professor Vijay P Misra;
peter.misra@virgin.net
ARTICLE SUMMARY
Article focus
- Development and application of a novel multi-
modal deﬁnition of treatment response in a
non-interventional study of patients with CD
administered BoNT-A in routine clinical practice.
Key messages
- Magnitude of effect, subject satisfaction and
safety proﬁle are appropriate measures of
BoNT-A response in patients with CD.
- A multidimensional deﬁnition of response
enables comprehensive evaluation of treatment
response that is not achievable with a single
measurement criterion.
Strengths and limitations of this study
- This is a large-scale study of CD patient
demographics and BoNT-A response in a real-life
clinical setting.
- The subjective nature of self-reported waning of
treatment effect is potentially vulnerable to bias
as a result of high patient expectation, which
constrains its use as part of the challenging
multidimensional deﬁnition of response.
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6 There is a substantial body of evidence
from clinical studies to support the use of BoNT-A in
patients with CD.
57 e9 There are currently three major
commercially available preparations of Type A toxins:
abobotulinumtoxinA (Dysport
,I p s e n ,B o u l o g n e - B i l l -
ancourt, France), onabotulinumtoxinA (Botox
, Allergan
Incorporated, Irvine, CA, USA) and incobotulinumtoxinA
(Xeomin
, Merz Pharmaceuticals GmBH, Frankfurt,
Germany), which differ in their potency; thus, the units of
each preparation are not directly interchangeable. BoNT-B
has also gained acceptance in the treatment of patients
with CD resistant to treatment with BoNT-A.
10
The administration of BoNT-A in practice does not
reﬂect the standardised methods adopted in clinical
studies because injection schemes are individually deter-
mined by the physician. Moreover, BoNT-A administration
protocols for CD are not standardised to the subtypes of
the condition (ie, predominant and secondary compo-
nents for head and neck deviations). Although the efﬁ-
cacy and safety of BoNT-A is widely accepted according to
robust and well-designed clinical trials, these studies
assessed efﬁcacy using mainly Toronto Western Spasmodic
Torticollis Rating Scale (TWSTRS) or Tsui scale in highly
selected patients, which may not relate to real-life practice
with individualised patients.
In clinical practice, assessment of BoNT-A effectiveness is
multidimensional and cannot be limited to TWSTRS or
Tsui scale only, but data on efﬁcacy and safety of BoNT-A in
real-worldsettingsarelacking.Thereis,therefore,aclinical
need to pragmatically describe the management of CD
subtypes innovatively, taking into account several dimen-
sions of interest for physicians, such as patient’s satisfac-
tion, and to establish a robust deﬁnition of response to
BoNT-A treatment in the real-life management of patients
with CD. A meeting of experienced neurologists from
France, Germany, Italy, Russia, Spain, Thailand and the UK
was convened in 2008, with a view to reaching a consensus
on a deﬁnition of treatment response, a deﬁnition
currently lacking in the clinical management of patients
withCDreceivingBoNT-A.Theexpertgroupidentiﬁedthe
most relevant predominant and secondary components for
head and neck deviations and concurred in proposing
a new multidimensional deﬁnition of response, which was
based on combined aspects of efﬁcacy and tolerability and
assessment of global improvement. We present, herein,
ﬁndings from the application of this novel deﬁnition of
treatment response in a non-interventional study of
subjects with CD who were administered BoNT-A. In this
study, the primary objective was to estimate the responder
rate following one BoNT-A injection cycle administered via
routine practice. Prognostic factors for response were
evaluated as an additional exploratory analysis.
SUBJECTS AND METHODS
Study design
This was an international, multicentre, observational,
prospective, longitudinal study. Informed consent was
obtained prior to subject enrolment and prior to any data
collection. Independent Ethics Committee/Institutional
Review Board approval in each country was obtained prior
to study initiation.
Study population
This study enrolled subjects $18 years old, suffering
from idiopathic CD with a TWSTRS severity score $15
9
and a $12-week interval between the last injection
(BoNT-A or BoNT-B) and the ﬁrst study visit.
To create a homogeneous population for study, subjects
with secondary CD were excluded from the study, as were
subjects with contraindications of BoNT-A treatment.
Study treatment
The decision to prescribe a BoNT-A preparation was
taken prior to, and independently from, the decision to
enrol the subject in the study. In order to avoid bias in
the recruitment of subjects, physicians were not allowed
to choose their subjects but were asked to include con-
secutive subjects during BoNT-A consultations.
The prescribing of BoNT-A was made in accordance
with routine clinical practice and investigators were free
to choose: the targeted muscles from the clinically indi-
cated neck muscles; BoNT-A preparation; and injected
dose number of points and volume per point. Subjects
received a single injection cycle as part of normal clinical
practice. Concomitant therapy was permitted throughout
the study.
Study assessments
Subjects were assessed during their usual centre visits at
the inclusion visit (visit 1; week 0), follow-up visit (visit 2;
3e6 weeks after injection) and end-of-study visit (visit 3;
12e16 weeks after injection). Efﬁcacy assessments en-
compassed clinical assessment, assessment of CD using
the TWSTRS total score (recorded at all visits)
11, assess-
ment of tremor using the Tsui Tremor subscale (recorded
at all visits)
12, assessment of Clinical Global Improvement
(CGI) by both investigator and subject (recorded at
visit 2) and CD Impact Proﬁle-58 (CDIP-58) (recorded
at visits 1 and 2).
13 The CDIP-58 comprises a 16-item
health-related quality of life (HRQoL) questionnaire
encompassing domains relating to head and neck
symptoms experienced by the subject, impact on usual
daily activities, physical activities, sleep, social activities
and emotions/psychosocial functioning. Scores for items
within domains were summarised into eight subscale
scores, each ranging from 0 to 100 (higher scores indicate
worse health).
The primary end point of this study was the percentage
of responders after one BoNT-A injection cycle. Response
was deﬁned using the ambitious hypothesis for a multidi-
mensional deﬁnition of response developed by experi-
enced neurologists, whereby subjects were classiﬁed as
a responder if they met all the following criteria: (1)
magnitude of effect: $25% improvement on TWSTRS
severity scale at visit 2 (peak effect) or visit 3 (if visit 2 was
not performed), compared with visit 1, as reported by
Truong et al
9; (2) duration of effect: $12-week interval
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subject reports a clinically relevant waning of treatment
effect, justifying a reinjection cycle as reported by
Ranoux et al
14; (3) good tolerance: no treatment-related
severe adverse event (AE) reported during the study and
(4) improvement in subject-rated CGI score at visit 2 and
visit 3 (equal to either +2 (much improved) or +3 (very
much improved)).
Secondary efﬁcacy outcomes included improvements
in TWSTRS total and Severity, Disability and Pain sub-
scale scores, tremor (as measured by Tsui score) and
CDIP-58.
Only AEs considered by the investigator to be related
to study drug were collected during this study, which is in
line with current clinical practice. Investigators were
asked to report, to the safety department of the BoNT-A
manufacturer, any adverse drug reactions using the usual
process for such reactions. More speciﬁcally on visits 2
and 3, investigators were also requested to document the
occurrence and intensity (severe or not) of dysphonia,
dysphagia, neck muscle weakness and other.
Study size
The sample size was determined based on both the
primary and exploratory objectives (prognostic factors for
response). Considering an anticipated rate of responder
of 50%, using an estimate for this proportion with a
precision of 5%, the required sample size was determined
to be 385 subjects (assuming a two-sided 95% CI). When
considering the objective related to the detection of
prognostic factors (assuming a¼5%, power¼80%), in
order to ensure the ability to detect OR $2 and a prob-
ability to be exposed to any given level of a prognostic
factor larger or equal to 1/3 (¼imbalance), the required
sample size is 366 subjects. Thus, in order to ensure 385
evaluable subjects, 400 subjects were included in this
study.
Statistical analyses
The safety population consisted of all subjects who
received one BoNT-A injection, whereas the efﬁcacy
population comprised all subjects in the treated popu-
lation for whom there were data for each of the four
underlying variables for response. The responder anal-
ysis was performed using the efﬁcacy population, and
all secondary end points were assessed using the safety
population.
The primary end point was summarised overall, and by
each of the four criteria, as the percentage of responders
as a point estimate and its associated 95% CI. Responder
subgroup analyses were also performed to investigate
response based on the following criteria: predominant
component of head/neck rotation, BoNT-A preparations,
duration of CD, previous BoNT-A use, dystonia local-
isation (head/neck, trunk, limbs), presence of tremor
based on the Tsui scale, use of electromyography and use
of concomitant therapies at baseline.
As an exploratory analysis, a stepwise multivariate
logistic regression analysis was performed on the efﬁcacy
population to assess prognostic factors for response
using subgroup variables, as well as additional demo-
graphic and disease characteristics variables. ORs with
95% CI estimated by the logistic model were calculated
using the primary criteria; a lower 95% CI bound >1
indicated a signiﬁcantly increased chance of being a
responder.
No estimations were made for missing data, and there
was no controlling for confounding factors.
RESULTS
Subject population
Between 19 February 2009 and 12 February 2010, 404
subjects from 38 centres in nine countries (Australia,
Belgium, Czech Republic, France, Germany, The
Netherlands, Portugal, Russia and the UK) were
enrolled and followed in this study. A total of 379
subjects (93.8%) completed the study. The most common
reason for not completing the study was loss to follow-up
(3.2%; n¼13); no subjects discontinued due to lack of
efﬁcacy. The safety population included all subjects
treated with BoNT-A (n¼404), whereas the efﬁcacy
population included all subjects treated with BoNT-A for
whom data were available for each of the four criteria for
the primary end point (n¼367).
Baseline demographic and disease characteristics
are shown in table 1. The majority of subjects were
women (64.9%), aged 41e60 years (52.5%) and had
suffered from CD for >1 year (90.9%). Nearly all the
subjects had sporadic CD (94.8%), and focal dystonia
predominated (91.6%). In the few cases of segmental/
multifocal dystonias, the upper limb was the most fre-
quently impaired segment. The most common predom-
inant component of CD was rotation (72.8%), followed
by laterocollis (14.1%). The majority of subjects had
secondary components (83.9%).
Treatment history
Most subjects had previously received a BoNT-A injection
(84.9%). A minority of patients had prior history of treat-
ment with BoNT-B (5.7%). Of the safety population, more
than half of subjects (n¼215; 53.2%) had previously re-
ceived benzodiazepines for the treatment of CD and ap-
proximately one-third (29.7%) continued to receive these
agents after BoNT-A treatment. Prior physical therapy was
reported in 49.8% of subjects, but only 14.6% of subjects
were receiving physical therapy at the inclusion visit. Anal-
gesics had been previously taken by 40.8% of subjects, with
18.3% of subjects receiving analgesics at the inclusion visit.
Injection schemes
Physicians prescribed three BoNT-A preparations:
Dysport (n¼279, 69%), Botox (n¼113, 28%) and
Xeomin (n¼12, 3%), independently from study enrol-
ment, as per local clinical practice at the centre. Subjects
received Dysport and Botox at median doses of 500 and
160 units, respectively. Overall, 90% of patients received
<1000 U of Dysport and 300 U of Botox. In total, the
median number of injected muscles was four, of which,
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and Botox groups were the splenius capitis, sternoclei-
domastoid and trapezius. For Xeomin, the median dose
was 200 units, although small patient numbers make
results difﬁcult to interpret. Investigators used electro-
myography during administration of at least one muscle
in 185 subjects (46.0%).
Efﬁcacy
Responder analysis
The percentage of subjects meeting the response criteria,
as well as each of the individual response criteria, is shown
in ﬁgure 1. Three criteria out of four were achieved in the
majority of patients, as shown by 97.5%, 73.6% and 69.8%
of subjects achieving the criterion of magnitude of effect,
tolerance (absence of severe related AEs) and subject’s
CGI, respectively. A total of 49.3% of subjects achieved
response based on the duration of effect criterion
($12 weeks between inclusion and subject-rated waning
of treatment effect). Overall, 28.6% (95% CI 24.0% to
33.5%) of subjects were classiﬁed as responders to treat-
ment. Evaluation of response by TWSTRS, tolerance and
CGI improvement alone (ie, exclusion of duration of
effect) established 58.3% (95% CI 53.1% to 63.4%) of
subjects as responders.
Responder subgroup analysis
Analysis of the response criteria by subgroup is shown
in ﬁgure 2 and showed that there were variations in
Table 1 Subject demographics and CD characteristics
(safety population)
Demographic characteristic Total, n[404
Gender, n (%)
Male 142 (35.1)
Female 262 (64.9)
Age (years), n (%)
18e30 18 (4.5)
31e40 52 (12.9)
41e50 105 (26.0)
51e60 107 (26.5)
61e70 81 (20.0)
>70 41 (10.1)
Body weight (kg), mean (SD) 72.8 (14.9)
Duration of cervical dystonia, n (%)
<6 months 10 (2.5)
6 months to <1 year 27 (6.7)
1e5 years 140 (34.7)
6e10 years 89 (22.0)
11e20 years 84 (20.8)
>20 years 54 (13.4)
Type of cervical dystonia, n (%)
Sporadic 383 (94.8)
Familial 21 (5.2)
Location type, n (%)
Focal 370 (91.6)
Segmental 20 (5.0)
Multifocal 9 (2.2)
Generalised 5 (1.2)
Localisation, n (%)
Head/neck 404 (100.0)
Trunk 13 (3.2)
Upper limb 29 (7.2)
Lower limb 6 (1.5)
Predominant component, n (%)
Rotation 294 (72.8)
Laterocollis 57 (14.1)
Tremor 20 (5.0)
Retrocollis 12 (3.0)
Shoulder elevation 8 (2.0)
Anterocollis 4 (1.0)
Jerk 4 (1.0)
Lateral shift of column 3 (0.7)
Sagittal shift of column 2 (0.5)
Secondary components present, n (%)
Yes 339 (83.9)
Most frequent combinations of predominant and secondary
components, n (%)
Rotation and laterocollis 161 (39.9)
Rotation and shoulder elevation 143 (35.4)
Rotation and tremor 73 (18.1)
TWSTRS score at baseline, mean 6 SD
Severity subscale 19.563.8
Disability subscale 10.665.9
Pain subscale 6.664.9
Total score 36.8610.7
Baseline tremor present, n (%) 191 (47.3)
CDIP-58 subscales scores*, mean 6 SD
Head and neck symptoms 50.6625.2
Pain and discomfort 31.8627.8
Upper limb activities 26.1624.6
Continued
Table 1 Continued
Demographic characteristic Total, n[404
Walking 22.4626.7
Sleep 23.0631.0
Annoyance 26.4627.7
Mood 21.6625.9
Psychosocial 30.7628.2
*CDIP-58, n¼99 (questionnaire in English, thus completed by
English-speaking patients only).
CD, cervical dystonia.
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Figure 1 Responder analysis. AEs, adverse events; CGI,
Clinical Global Improvement; TWSTRS, Toronto Western
Spasmodic Torticollis Rating Scale.
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niﬁcant. Data revealed that more subjects responded
among subgroups presenting with laterocollis (41.7% vs
26.7% with rotation), without baseline tremor (33.2% vs
23.7% with tremor), and those not receiving concomi-
tant medication at baseline (35.1% vs 22.8% receiving
baseline concomitant medications).
Prognostic factors associated with response
T h em u l t i v a r i a t el o g i s t i cr e g r e s s i o ns h o w e dt h a tt h em o s t
strongly associated factor to response was age (<40 years;
OR 3.9, p<0.05). Additional trends with a lower magnitude
of association were observed (data not shown).
Secondary efﬁcacy outcomes
Secondary efﬁcacy outcomes are shown in table 2.
Subjects reported a notable improvement in TWSTRS
total score and subscale scores over the course of treat-
ment, as indicated by the percentage change in scores at
each visit. Sixty-six of the 181 subjects (36.5%) with
baseline tremor no longer presented with tremor at
visit 2. HRQoL improved following BoNT-A treatment, as
demonstrated by decreases in all eight subscores of the
CDIP-58 at visit 2.
Safety and tolerability
A total of 88 treatment-related AEs were reported during
the study. Overall, 68 subjects (16.8%) experienced at
least one treatment-related AE. Of the observed AEs,
dysphagia was the most commonly reported (9.2%).
Overall, 10 treatment-related AEs were considered to be
severe, with neck muscle weakness (n¼4) being observed
as the most common AE at this grade of severity. The
incidence of AEs (severe and not severe) and dysphagia
did not statistically differ between BoNT-A preparations
(ﬁgure 3).
DISCUSSION
In this non-interventional study of subjects with CD in
routine practice, the majority of subjects were middle-
aged women. These demographic data were in accor-
dance with a typical population of subjects with CD.
15
TWSTRS and CDIP-58 scores at baseline reﬂected a
population with moderate to severe CD severity.
Real-life data on response to BoNT-A in CD are rela-
tively sparse,
16e18 and studies evaluating multidimen-
sional deﬁnitions of response, in particular, are lacking.
Therefore, the primary objective of this study was to
estimate the rate of response following one BoNT-A
injection cycle in real-life practice using a challenging
multidimensional deﬁnition developed by an expert
group of neurologists. To our knowledge, this is the ﬁrst
such non-interventional study to apply a consensus-based
multimodal deﬁnition of response to a large real-world
population of patients with CD treated with BoNT-A. In
the interpretation of our ﬁndings, it should be borne in
mind that clinical studies have commonly utilised a single
or co-primary end point.
19 20 Thus, the requirement to
achieve four primary end points within the multidimen-
sional response deﬁnition proposed in this study repre-
sented a signiﬁcant challenge. Notably, this ambitious
deﬁnition for response was achieved by almost one-third
(approximately 30%) of the 404 subjects who participated
in this study. Although the magnitude of effect and subject
satisfaction were both high and the number of treatment-
related severe AEs was very low, the number of subjects
with a duration of effect $12 weeks was relatively low. This
is in contrast to published observations that suggest that
patients experience a duration of effect (mean or total)
beyond 12 weeks, as shown in controlled trials of Dysport
and Botox.
69Considering three primary endpoints, that is
with the exclusion of the duration of effect criterion,
approximately 60% of patients achieved response. In the
clinical experience of the expert group of neurologists,
thelevelofresponseachievedwiththreeor fourco-primary
end points is highly encouraging. Therefore, our novel
ﬁndings indicate that measurements for the magnitude of
effect, subject satisfaction and safety proﬁle according to
routine practice demonstrate good clinical response to
BoNT-AinsubjectssufferingfromCD.However,durationof
effect, such as deﬁned in the study, may require further
conﬁrmationduetoitssubjectivenature.Waningofeffectis
a gradual process and therefore assessment for duration of
effect based on serial subject’s CGI measurements (rather
Figure 2 Subgroup analyses of
responders (efﬁcacy population).
BoNT-A, Botulinum toxin A;
CD, cervical dystonia;
EMG, electromyography.
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effect on a single speciﬁc date) may have been more
appropriate. Regardless of these considerations, unre-
alistically high patient expectations and subjectivity may
inﬂuence the perception of quick waning of effect. This
highlights that, for some patients, this aspect is seen as a
hurdle to response.
The subgroup analyses suggest that laterocollis as a
predominant component, the absence of baseline tremor
and absence of concomitant medication are factors that
may be associated with higher response rates. Even if these
data were not statistically signiﬁcant, they provide a good
starting point for further evaluation. In particular, it would
be interesting to establish whether the use of concomitant
medication at baseline reﬂects a greater disease severity
(as assessed with TWSTRS scores) or more co-morbidities
associated with CD (eg, anxiety, depression) that could
interfere with the therapeutic effect of BoNT-A. With
relevance to the former, data from this study suggest that
t h ed u r a t i o no fC D( #10 years vs >10 years) did not
markedly inﬂuence the distribution of concomitant
therapies (data not shown).
Efﬁcacy ﬁndings conﬁrm the value of BoNT-A as a
treatment for CD symptoms. Notable improvements in
mean TWSTRS scores were observed, as was improvement
in tremor. It is recognised that HRQoL is compromised
in CD, especially among women.
20 In this analysis of a
largely female population, the decrease in subscores of the
CDIP-58 (a more sensitive measure of clinical change than
other frequently used HRQoL instruments
13) is consistent
with previous reports in conﬁrming the positive impact of
BoNT-A on HRQoL when administered as a therapy
for CD.
21 22
BoNT-A was generally well tolerated in this study, with
few reported severe AEs. In general, treatment-emergent
side effects were consistent with the known safety proﬁle
of this treatment.
6 As observed in previous reports, the
most common side effect of BoNT-A treatment was
dysphagia.
62 0Overall, this study highlights that no new
safety concerns were raised with BoNT-A when used in
routine clinical practice. For any given treatment, an
acceptable level of tolerance is required to ensure
continued treatment and subject compliance, hence, the
inclusion of tolerance as a response criterion. In total,
97.5% of subjects met the response criterion of no severe
treatment-related AEs. It may be speculated that the
presence of treatment-emergent side effects such as
dysphagia could exert a negative impact on objective and
subjective assessments of symptom improvement and
ultimately response, but observed response rates of
73.6% (magnitude of effect) and 69.8% (subject’s CGI)
in this study would suggest otherwise.
Inherent to studies of this design (non-interventional),
the lack of randomisation, as well as the absence of
a control group, means that conﬁrmatory conclusions
Table 2 Efﬁcacy outcomes
Visit 2 Visit 3
Percentage change in TWSTRS score, mean 6 SD (n¼374) (n¼380)
Severity subscore e40.8625.1 e16.5622.3
Disability subscore e36.3649.8 e6.6690.2
Pain subscore e35.8649.9 e7.6672.6
Total score e39.6626.6 e15.4627.0
Tremor (n¼375y)( n ¼380)
Subjects with improvement in tremor* with treatment, n (%) 66/181y(36.5) 41/178* (23.0)
CDIP-58 subscales scores, mean 6 SD (n¼93z) e
Head and neck symptoms 26.1621.9 e
Pain and discomfort 20.5623.5 e
Upper limb activities 16.3619.9 e
Walking 15.3621.5 e
Sleep 12.3620.0 e
Annoyance 15.6623.9 e
Mood 13.9620.5 e
Psychosocial functioning 19.2623.6 e
*Improvement deﬁned by presence of tremor at baseline and absence of tremor at subsequent visits.
ySubjects with data available at this timepoint and with tremor present at baseline.
zQuestionnaire in English, thus completed by English-speaking patients only.
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Figure 3 Occurrence of AEs with frequently used BoNT-A
preparation. AEs, adverse events; BoNT-A, Botulinum toxin A.
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BoNT-A in idiopathic cervical dystoniacannot be drawn. Moreover, the ap r i o r ideﬁned duration
of effect criteria was based on subject assessment of the
waning of treatment effect. Thus, the subjective nature of
this assessment has potential for bias resulting from
patients’ unrealistically high expectations from treatment,
a hypothesis supported by the observation of maintained
improvements in TWSTRS scores even at visit 3.
CONCLUSIONS
This study reveals the CD subject demographics and
BoNT-A response in a real-life clinical setting. Using a
novel multimodal deﬁnition of response, this large-scale
study showed that the magnitude of effect, subject sat-
isfaction and safety proﬁle were well met, and it was
also felt that these were appropriate measures to assess
BoNT-A response in CD subjects. This study also indi-
cates possible predictive factors for BoNT-A in subjects
with CD, but further research is required to conﬁrm
these in the prognosis of CD.
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